Exploring the Gut Microbiota and Cardiovascular Disease

Area of Science:

• Microbiology
• Cardiovascular Medicine
• Metabolomics

Background:

• Cardiovascular disease (CVD) is a major global health burden.
• Established CVD risk factors include smoking, hypertension, and diabetes.
• The gut microbiota's role in health and disease, including CVD, is increasingly recognized.

Purpose of the Study:

• To review the current understanding of the gut microbiome's involvement in CVD development.
• To explore the relationship between microbial communities, their functions, and metabolic profiles in CVD.
• To discuss therapeutic strategies targeting the gut microbiota for CVD.

Main Methods:

• Literature review of studies investigating the gut microbiome and CVD.
• Analysis of microbial metabolites (e.g., SCFAs, bile acids, TMAO) and their association with CVD risk.
• Examination of therapeutic interventions modulating the gut microbiota.

Main Results:

• Gut microbiota composition and function are linked to CVD development.
• Microbial metabolites such as TMAO are associated with increased CVD risk.
• Probiotics and fecal microbiota transplantation are emerging as potential CVD therapies.

Conclusions:

• The gut microbiome plays a significant role in cardiovascular health and disease.
• Microbial metabolites represent key mediators in the gut-heart axis.
• Modulating the gut microbiota holds promise for novel CVD prevention and treatment strategies.